Business Wire (Mon, 6-Jul 8:00 AM ET)
Business Wire (Thu, 4-Jun 7:00 AM ET)
TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.
PRNewswire (Wed, 3-Jun 12:44 AM ET)
Business Wire (Thu, 7-May 8:00 AM ET)
Market Chameleon (Thu, 26-Feb 3:38 AM ET)
Aurinia Sets November 4 for Earnings Reveal—Investors Eye Business Update as New Therapies Advance
Market Chameleon (Tue, 4-Nov 5:41 AM ET)
Market Chameleon (Tue, 4-Nov 3:43 AM ET)
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Aurinia Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol AUPH.
As of July 13, 2026, AUPH stock price climbed to $16.03 with 1,229,496 million shares trading.
AUPH has a beta of -0.16, meaning it tends to be less sensitive to market movements. AUPH has a correlation of 0.00 to the broad based SPY ETF.
AUPH has a market cap of $2.06 billion. This is considered a Mid Cap stock.
Last quarter Aurinia Pharmaceuticals - Common Shares reported $78 million in Revenue and $.25 earnings per share. This beat revenue expectation by $642,032 and exceeded earnings estimates by $.06.
In the last 3 years, AUPH traded as high as $19.25 and as low as $4.71.
The top ETF exchange traded funds that AUPH belongs to (by Net Assets): IWM, IWO, IBB, VTWO, FESM.
AUPH has outperformed the market in the last year with a return of +79.5%, while the SPY ETF gained +20.9%. However, in the most recent history, AUPH shares have underperformed the stock market with its stock returning +1.7% in the last 3 month period and -7.0% for the last 2 week period, while SPY has returned +10.5% and +2.8%, respectively.
AUPH support price is $15.23 and resistance is $16.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUPH shares will trade within this expected range on the day.
